Tag Archives: Clinical Trials

Jace Ward’s Friends Can’t Wait

Posted on July 21, 2021 by Team Captain

We will remember our friend Jace as a wonderful, positive, fun loving, selfless guy who enjoyed life, loved his friends, his family and his God. To some, he may be remembered as an outstanding national advocate for DIPG research, or … Continue reading →

Posted in Cancer, Childhood Cancer, DIPG, Pediatric Cancer, Rare Disease, Uncategorized | Tagged Arms Wide Open Childhood Cancer Foundation, CAR T Cell, Chimeric Antigen Receptor T Cells, Clinical Trials, Diffuse Intrinsic Pontine Glioma, DIPG, Jace Ward, Lisa Ward, Neal Armstrong, Nurse Practitioner, Ommaya Catheter, Stanford, Storm the Heavens | Leave a comment

The Fault in Our Systems

Posted on July 29, 2014 by Team Captain

by Nathan Traller, Nathalie’s father Editor’s Note: Nathan’s daughter was diagnosed with Aveolar Soft Part Sarcoma (ASPS) two years ago and he has been fighting to get her into a possible life saving clinical trial for PD1 and PDL1. Time … Continue reading →

Posted in Cancer, Childhood Cancer, Pediatric Cancer, Rare Disease, Uncategorized | Tagged 2.0 clinical Trials, ASCO, ASPS, Aveolar Soft Part Sarcoma, Bristol-Myers Squibb, Clinical Trials, Compassionate use, FDA, Genentech Inc., genomic profile, Lung MAP trial, Merck, metastatic cancer, Nathan Traller, National Cancer Institute, National Institutes of Health, NCI, NIH, PD1, PDL1, pediatric trials, rare disease, tumor bank | 3 Comments

Adrift in the Waters of Childhood Cancer-Arguing to Change the Standard of Care

Posted on May 16, 2013 by Team Captain

April 11, 2008 will always remain etched in my memory for one simple reason. It is the day that we heard the words “your daughter has cancer.” They are four of the worst words that a parent could ever imagine … Continue reading →

Posted in Cancer, Childhood Cancer, Pediatric Cancer, Rare Disease, Uncategorized | Tagged Alexis, Children's National Medical Center, Clinical Trials, Dana Farber, DIPG, integrated team, Johns Hopkins, Jonathan Agin, NIH, patient advocate, social worker, standard of care | Leave a comment

Cancer Drug’s Valley of Death – Where is it, What is it?

Posted on January 13, 2013 by Team Captain

To truly understand the problems with development of drugs specific to childhood cancer, and rare disease in general, examine the FDA’s Therapeutic Development Pipeline below. The pipeline represents the normal development of an average drug. The average successful drug will … Continue reading →